Introduction
The rate of renewal of the skeleton in most patients with osteoporosis is about 5%0 yearly.1 2 Thus any treatment aimed at rapidly reversing a typical9 20% relative deficit in bone mass must increase the rate of formation of new bone. We have reported that giving low doses of synthetic human parathyroid hormone fragment (PTH 1-34) daily for six months roughly doubles the bone formation rate. 4 We report here further results from our multicentre study.
Patients and methods
Sixteen women aged 49 to 78 years (mean 63) and five men aged 52 to 61 years (mean 56) were studied. Each gave informed consent to participation in the trial in the manner approved by his or her local hospital ethical committee. All but one had at least one severe vertebral crush fracture (the mean number being five: the remaining patient had a history of fractures of long bones (table) . No patient had received fluoride treatment or a prolonged course of glucocorticoid treatment. The only known precipitating cause for osteoporosis apart from a lack of oestrogen was thyrotoxicosis. This had occurred in one patient and had been successfully treated 35 years before the trial. At the time of acceptance into the study no patient had received pharmacological doses of any vitamin D preparation within two years, although one patient in Boston (case 21) was treated with vitamin D3 50 mg (2000 IU) daily for two years before entering the trial, and all the British patients (cases [1] [2] [3] [4] [5] [6] [7] [8] were given vitamin D. 12 -5 mg (500 IU) daily from three months before their baseline values were determined. These doses were maintained throughout the study.
The following indices were normal in all patients: liver function tests, age-corrected and size-corrected glomerular filtration rates, plasma calcium and phosphate concentrations, alkaline phosphatase activity, thyroxine and cortisol concentrations, 24-hour urinary calcium and hydroxyproline excretions, faecal fat excretion, and blood count. Three women (cases 21, 24, and 41) were given oestrogen replacement treatment for at least 10 months before entering the study and throughout it. The remaining 14 women were postmenopausal. One of the men (case 43) was given a course of testosterone preparations of the same dose throughout the study.
The degree of incapacity that each patient experienced was assessed before treatment and at the end of treatment on the following scale: 5-bedridden; 4-confined to bed, chair, or wheelchair; 3-ambulatory but lying down more than 12 hours daily; 2-ordinary activities limited by pain; 1-only strenuous activities limited by pain; 0-no activities limited by pain.
KINETICS
The schedule of preliminary investigations, the analytical methods, and the treatment protocol have been described.4 6 In 19 patients all the studies outlined above were repeated six months after the start of treatment, second biopsies being performed on the other iliac crest when treatment was stopped. The other two patients continued treatment for longer: one (case 22) was studied after six months on 740 U/day and again six months later on a reduced dose of 500 U/day; the other (case 21) was studied after 18 months on 740 U/day and again six months later after reduction of the dose to 400 U/day in the 19th month.
Cortical bone densitometry was performed using 125I-absorptiometry at the junction of the proximal two-thirds of the radius with the distal third in 14 cases,'4 and using 241Am-absorptiometry at the junction of the proximal four-fifths of the femur with the distal fifth in cases 1-8.1'
Results

CLINICAL FINDINGS
No side effects of treatment were noted except transient redness and itching at the injection site in one patient. No qualitative or quantitative changes occurred in any of the formed elements of the blood in association with treatment.
As assessed clinically and by repeat radiography of the dorsal and lumbar spine only one patient suffered a further vertebral fracture during the six-month treatment period. She had earlier reported pain apparently related to this fracture during her baseline study.
Clinical and laboratory findings and results of bone biopsy before and (unless otherwise stated) six months after treatment with human parathyroid hormone fragment in 21 Histomorphometry of the iliac biopsy samples also showed co'nsiderable increases in trabecular bone volume in nine out of the ten pairs of biopsy samples satisfactory for this measurement (fig 1) . The mean increase was from a mean volume of 9-3 % to a mean volume of 17-3% (+92% of baseline value). Because the data were skewed they were corrected for determining the level of significance by assessing a logarithmic transformnation of the ratios of the values of the second biopsy samples to those of the first. The mean increase thus calculated was under 92% (+70% of baseline). This increase was significant at the 1 of 39%0 to a mean of 6 2 %. For technical reasons it was possible to count osteoclasts in only six pairs of biopsy samples. In all but one case their numbers increased. The seven technically adequate pretreatment biopsies yielded a mean osteoclast count of 0 19±0 05/mm2, and the 14 post-treatment biopsies yielded a mean value of 0 62± 0 14/mm2 (t-2 89, p<002).
Discussion
The increases in trabecular bone volume in these patients treated with synthetic human parathyroid hormone fragment (PTH 1-34) resulted from the formation of new bone on the surface of existing trabeculae, which was shown on detailed examination to be fully mineralised and of normal lamellar texture. Vertebrae, which are normally more than threequarters composed of trabecular bone, are dependent for their resistance to compressive forces on their bone mineral content, 16 and there appears to be greater loss of trabecular bone than cortical bone in osteoporosis.3 17 18 Hence the observed increases in trabecular bone volume produced by treatment with this hormone fragment might usefully increase the strength of the vertebrae in patients with axial osteoporosis.
Because of the relatively wide distribution of the values of the trabecular bone volumes at the time of the second biopsy we attempted to find a measured variable that would provide a predictor to the outcome of treatment, using the trabecular bone volume as the endpoint. A close relation was found between the 47Ca-accretion rate achieved before the end of treatment and final trabecular bone volume (fig 2) . The regression line shown was described by the equation: Y 079x+4 51±5 32 (t=5-0, p <0001, r=0-81). Individual changes in trabecular bone volume also correlated well with maximum changes in 47Ca-accretion rate. The regression line was described by the equation: Y=0O97x-1-62±6-07 (t= 3-9, p <0-01, r= 0-81). These results strongly suggest that the size of the improvement in trabecular bone volume is somehow related to the size of the maximum change in 47Ca-accretion rate. Further work is planned to test whether measurement of the accretion rate provides a useful indicator for titrating an effective dose in individual patients.
Despite the encouraging changes in trabecular bone, cortical bone density did not show comparable increases. Furthermore, the balance studies showed no net retention of calcium or phosphate, although the pronounced increases in trabecular bone would have consumed an average of at least 12 mmol calcium/24 h (481 mg/24 h) over six months. These data suggest that the observed increases in trabecular bone were partly at the expense of cortical bone, and some supporting evidence for this is provided by studies on a subgroup of eight patients whose bone density was measured more often than that in the others and in whom changes in calcium balance correlated closely with changes in bone density in the distal femur (Hesp et al, unpublished observations). The adverse trend in cortical bone density associated with treatment, however, was small and could account for only a minor part of the increase in trabecular bone.
The implications of this study for treatment are intriguing since the only other treatments-so far shown to have increased trabecular bone volume in osteoporosis used sodium fluoride in doses associated with a high incidence of side effects. '9 20 Compared with our results in rats,21 the failure of human parathyroid hormone fragment to increase dietary calcium absorption was surprising and may have limited the ability of our patients to increase cortical bone mass. Perhaps the increases in plasma concentration of hormone fragment associated with our mode of administration were so brief that the renal lahydroxylase responsible for The fact that propranolol acutely suppressed PTH and calcitonin secretion in uraemic patients indicates that further studies are warranted to assess the long-term effects of the drug on the secretion of these hormones and on renal osteodystrophy. The contrast between the responses to propranolol and metoprolol supports the concept that PTH and calcitonin secretion is modulated through specific beta2-receptors.
Introduction
Most uraemic patients suffer from two potentially serious complications: hypertension and renal osteodystrophy. In about 200% of the hypertensive patients the hypertension persists despite ultrafiltration and they need antihypertensive drugs.' Renal osteodystrophy in patients on long-term haemodialysis is caused mainly by osteitis fibrosa secondary to parathyroid hormone (PTH) hypersecretion.2 Insufficient secretion of calcitonin has, however, also been incriminated.8
Interactions between 3-adrenergic receptors and secretion of PTH and calcitonin have been shown. For example, in-vitro studies with radioactive hydroxybenzylpindolol4 have clearly shown the existence of 3-adrenergic receptors in the parathyroid tissue. Furthermore, the fact that isoprenaline had a greater effect in stimulating PTH and adenosine monophosphate secretion than epinephrine and epinephrine a greater effect than norepinephrine suggests that these receptors are of P2 type.' Finally, propranolol has been shown to prevent the increase of PTH secretion by catecholamines but not the increase induced by hypocalcaemia. The results of these in-vitro studies have been confirmed by in-vivo studies in animals,5 6 but studies in man have given inconsistent results. [7] [8] [9] [10] [11] [12] Direct evidence of the interaction of ,2-adrenergic receptors and calcitonin secretion has not been produced, but isoprenaline, epinephrine, and salbutamol have been shown to stimulate calcitonin secretion and propranolol to block it in vitro13 and in animals14 15 and normal men."' 17 In uraemic patients Heynen et al"7 have shown that propranolol can prevent the increase of calcitonin secretion induced by alcohol ingestion.
The data in man are therefore contradictory and concern only propranolol and not the newer cardioselective beta-blockers. Because these newer drugs may offer advantages over nonselective drugs (shorter titration duration, less frequent hypoglycaemia on dialysis, and less bronchoconstriction'8) their use is increasingly being considered in the treatment of hypertension in uraemic men. Since uraemic patients also have a secondary hyperparathyroidism the effects of these two types of betablockers on their PTH and calcitonin secretion may be relevant
